Merck & Co. Inc.

Company Overview

Merck & Co. Inc., formed in 1891, discovers, develops, manufactures, and sells pharmaceuticals and vaccines for human and animal healthcare. The company’s products reach drug wholesalers, retailers, hospitals, government agencies, and managed health care providers. Merck operates revenue in four primary regions: the U.S., Europe, Japan, the Middle East, and Africa.

The Company’s oncology portfolio, led by Keytruda, represented most of the company’s revenue. The company’s blockbuster cancer drug, Keytruda, is the dominant checkpoint inhibitor in the immuno-oncology space and has been approved for a long list of cancer indications. Merck is co-developing and co-commercializing Lynparza (olaparib) with AstraZeneca and Lenvima (lenvatinib mesylate) with Eisai Co. Ltd.

Financial Highlights (FY 2024)

Company's Business Segments

• Pharmaceutical : Human health pharmaceutical and vaccine products.
• Animal Health : Veterinary pharmaceutical and vaccine products, health management solutions and services.
• Other : These are primarily comprised of miscellaneous corporate revenues, including revenue hedging activities, as well as revenue from third-party manufacturing arrangements.